Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Annals of Oncology, September 2015, Oxford University Press (OUP),
DOI: 10.1093/annonc/mdv387.
You can read the full text:
Contributors
The following have contributed to this page
